Bergenin-activated SIRT1 inhibits TNF-α-induced proinflammatory response by blocking the NF-κB signaling pathway
Publication date: Available online 29 June 2020Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Min Chen, Cuifen Chen, Yun Gao, Dongming Li, Dan Huang, Ziyu Chen, Xuanna Zhao, Qiu Huang, Dong Wu, Tianwen Lai, Guomei Su, Bin Wu, Beixian Zhou (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - June 29, 2020 Category: Respiratory Medicine Source Type: research

The Effects of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase Inhibitor treatments on Lipopolysaccharide-induced Airway Inflammation in Mice
Publication date: Available online 13 May 2020Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Reshed Abohalaka, Turgut Emrah Bozkurt, Emirhan Nemutlu, Sevgen Celik Onder, Inci Sahin-Erdemli (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - May 15, 2020 Category: Respiratory Medicine Source Type: research

A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma
Publication date: Available online 7 May 2020Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Roland Buhl, Ana-Maria Tanase, Motoi Hosoe, Weihua Cao, Ivan Demin, Christian Bartels, Jürgen Jauernig, Dominik Ziegler, Francesco Patalano, Bettina Hederer, Frank Kanniess, Hanns-Christian Tillmann (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - May 8, 2020 Category: Respiratory Medicine Source Type: research

Mdivi-1 attenuates lipopolysaccharide-induced acute lung injury by inhibiting MAPKs, oxidative stress and apoptosis
Publication date: Available online 3 April 2020Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Songyun Deng, Lina Zhang, Yunan Mo, Yan Huang, Wenchao Li, Qianyi Peng, Li Huang, Yuhang Ai (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - April 4, 2020 Category: Respiratory Medicine Source Type: research

JMV5656, a short synthetic derivative of TLQP-21, alleviates acid-induced lung injury and fibrosis in mice
Publication date: Available online 20 March 2020Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Vanessa Zambelli, Laura Rizzi, Paolo Delvecchio, Elena Bresciani, Laura Molteni, Ramona Meanti, Verdiè Pascal, Jean-Alain Fehrentz, Robert J. Omeljaniuk, Giacomo Bellani, Antonio Torsello (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - March 21, 2020 Category: Respiratory Medicine Source Type: research

Tolerability of nintedanib-related diarrhea in patients with idiopathic pulmonary fibrosis
Publication date: Available online 20 March 2020Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Yasutaka Hirasawa, Mitsuhiro Abe, Jiro Terada, Masashi Sakayori, Kenichi Suzuki, Keiichiro Yoshioka, Takeshi Kawasaki, Kenji Tsushima, Koichiro Tatsumi (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - March 21, 2020 Category: Respiratory Medicine Source Type: research

Editorial Board
Publication date: April 2020Source: Pulmonary Pharmacology & Therapeutics, Volume 61Author(s): (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - March 18, 2020 Category: Respiratory Medicine Source Type: research

Determinants of response to bronchodilator in patients with cough variant asthma- A randomized, single-blinded, placebo-controlled study
Publication date: Available online 21 February 2020Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Fang Yi, Lina Han, Baojuan Liu, Xu Zhang, Yongxin Xue, Wei Luo, Qiaoli Chen, Kefang LaiAbstractBackgroundNot all patients with cough variant asthma (CVA) show responsiveness to bronchodilators (RB) in clinic. Whether there are specific clinical and pathophysiological features can indicate RB in patients with CVA needs further investigation. Thus, we aimed to investigate the RB in patients with CVA and associated factors.MethodsForty-two CVA patients were randomized in a 2:1 ratio to receive oral bambuterol hydroch...
Source: Pulmonary Pharmacology and Therapeutics - February 22, 2020 Category: Respiratory Medicine Source Type: research

Open triple therapy for chronic obstructive pulmonary disease: Patterns of prescription, exacerbations and healthcare costs from a large Italian claims database
ConclusionsThis large observational study based on claims data reliably identified subjects with COPD treated with open TT and their burden on the NHS. Moreover, it could describe the real clinical management of the open TT, before the marketing of the fixed one. These findings are useful for health policymakers in order to promote the appropriate utilization of both currently marketed and future therapies. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - February 22, 2020 Category: Respiratory Medicine Source Type: research

Hypertonic saline reduces cell infiltration into the lungs after brain death in rats
ConclusionsHSS is capable of reducing inflammatory cell infiltration into the lung after BD induction, which is associated with the reduction of ICAM-1 expression in organ vessels. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - February 8, 2020 Category: Respiratory Medicine Source Type: research

Bioequivalence studies of inhaled indacaterol maleate in healthy Chinese volunteers under gastrointestinal non-blocking or blocking with concomitant charcoal administration
ConclusionsThe results showed that 150 μg indacaterol (+/− 9 g charcoal) was well tolerated in all subjects. The two formulations are bioequivalent in terms of the rate and absorption both in charcoal-block and non-block conditions. The improved charcoal-based regimen demonstrated to be effective and fully blockade of GI absorption of indacaterol. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - February 8, 2020 Category: Respiratory Medicine Source Type: research

Effect of piperlongumine during exposure to cigarette smoke reduces inflammation and lung injury
Publication date: Available online 24 January 2020Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Monielle Sant’Ana Leal, Helena R. Souza, Lucas Possebon, Marinônio L. Cornélio, Yanira Riffo-Vasquez, Ana Paula Girol, Sonia M. OlianiAbstractChronic obstructive pulmonary disease (COPD) is related to smoking and anti-inflammatory therapy is indicated. Among the mediators with anti-inflammatory properties, we highlight piperlongumine (PL), an alkaloid/amide of Piper longum. Here we evaluated the PL administration on an experimental model of respiratory inflammation resulting from exposure to ciga...
Source: Pulmonary Pharmacology and Therapeutics - January 25, 2020 Category: Respiratory Medicine Source Type: research

Asthmatic children and MDI verbal inhalation technique counseling
In this study many children younger than 18 years old with asthma were collected from University hospital outpatient clinics throughout two years period Their MDI inhalation technique was checked and the number of MDI inhalation technique mistakes were detected and corrected at the first visit and every month for two more visits (three visits). Their peak expiratory flow (PEF) and forced expiratory volume in 1 s (FEV1) as a percentage of the forced vital capacity (FVC) were checked at every visit.Results81 asthmatic subjects (54 female) younger than 18 years old were collected with a mean (SD) age 14.4 (1.8) years old. M...
Source: Pulmonary Pharmacology and Therapeutics - January 25, 2020 Category: Respiratory Medicine Source Type: research

Dual use of bronchodilators versus monotherapy, and its impact on pulmonary rehabilitation in COPD patients
Publication date: Available online 21 January 2020Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Vicente Benavides-Cordoba, Sebastian Aviles, Camila Asc.ar, Lina Orozco, Ricardo Mosquera, Julian RiveraAbstractIntroductionLong-acting bronchodilators are the therapy with the best evidence for treating stable chronic obstructive pulmonary disease (COPD). Long-acting combinations of β2 agonists and anticholinergics (LABA-LAMA) are recommended in advanced stages when monotherapy has not generated the desired effects. Pulmonary Rehabilitation (PR) is an effective non-pharmacological strategy. The aim of this st...
Source: Pulmonary Pharmacology and Therapeutics - January 22, 2020 Category: Respiratory Medicine Source Type: research

Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life
Publication date: Available online 21 January 2020Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Sposato Bruno, Camiciottoli Gianna, Bacci Elena, Scalese Marco, Carpagnano Giovanna Elisiana, Pelaia Corrado, Santus Pierachille, Maniscalco Mauro, Masieri Simonetta, Angelo Corsico, Nicola Scichilone, Baglioni Stefano, Murgia Nicola, Folletti Ilenia, Bardi Giulio, Grosso Amelia, Cameli Paolo, Latorre Manuela, Antonino Musarra, Bargagli ElenaAbstractBackgroundMepolizumab (MEP) has been recently introduced to treat severe eosinophilic asthma. Trials have demonstrated a significant effectiveness in this phenotype. We...
Source: Pulmonary Pharmacology and Therapeutics - January 21, 2020 Category: Respiratory Medicine Source Type: research

Presence and function of β-adrenergic receptors in primary equine bronchial epithelia cells
Publication date: Available online 18 January 2020Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Linda Marie Schellenberg, Jana Bonicelli, Ina Hochheim, Ralf Regenthal, Getu AbrahamAbstractThe β-adrenergic receptor (β-AR) plays an important role in regulating a variety of cell and organ functions in different animal species and is an important target in asthma pathogenesis and therapy. The β-AR expression and function in equine bronchial epithelial cells (EBEC) were not known but innervation and significant decrease in receptor level were reported in the equine bronchial tissues from asthmatic h...
Source: Pulmonary Pharmacology and Therapeutics - January 18, 2020 Category: Respiratory Medicine Source Type: research

Editorial Board
Publication date: February 2020Source: Pulmonary Pharmacology & Therapeutics, Volume 60Author(s): (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - January 17, 2020 Category: Respiratory Medicine Source Type: research

Multiple single nucleotide polymorphisms of the transient receptor potential vanilloid 1 (TRPV1) genes associate with cough sensitivity to capsaicin in healthy subjects
ConclusionCapsaicin cough challenge sensitivity in healthy subjects is dependent on multiple TRPV1 polymorphisms. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - January 12, 2020 Category: Respiratory Medicine Source Type: research

Contribution of angiotensin II in hepatic ischemia /reperfusion induced lung injury: Acute versus chronic usage of captopril
ConclusionAngiotensin II plays a key role in tissue inflammation and airway hyperresponsiveness (AHR) via enhancing production of TNF-α. With more protection observed in lung, acute captopril could attenuate liver-induced lung injury via lowering TNF-α; a suggested possible mediator of airway hyperreactivity.Graphical abstract (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - January 9, 2020 Category: Respiratory Medicine Source Type: research

Eucalyptol reduces airway hyperresponsiveness in rats following cigarette smoke-exposed
ConclusionEUC reduces the hyperresponsiveness and the airway inflammatory profile, recovering the lung function. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - January 9, 2020 Category: Respiratory Medicine Source Type: research

Asthma phenotypes and T-bet protein expression in cells treated with Fluticasone Furoate/Vilanterol
In this study T-bet expression was attested in CD4 T cells treated with Fluticasone Furoate (FF), Vilanterol (V) and FF/V combination in severe asthmatic patients compared to patients with moderate asthma and healthy controls using Immunocytochemistry (ICC). First, CD4 T cells were isolated from PBMCs of 12 patients and controls using CD4 T cell isolation kit. Subsequently, isolated CD4 T cells were cultured with FF, V and FF/V for 1 h. To accomplish ICC, cells were incubated with anti-T-bet antibody, and then stained with HRP-bound secondary antibody. T-bet expression was evaluated using light microscopy. Statistical an...
Source: Pulmonary Pharmacology and Therapeutics - January 8, 2020 Category: Respiratory Medicine Source Type: research

Low penetrance of antibiotics in the epithelial lining fluid. The role of inhaled antibiotics in patients with bronchiectasis
Publication date: February 2020Source: Pulmonary Pharmacology & Therapeutics, Volume 60Author(s): Theodoros Karampitsakos, Ourania Papaioannou, Maria Kaponi, Andreana Kozanidou, Georgios Hillas, Elisavet Stavropoulou, Demosthenes Bouros, Katerina DimakouAbstractPlasma drug concentrations, spectrum of antibacterial activity and minimum inhibitory concentration (MIC) had been widely considered as markers of the efficacy of antibiotics. Nonetheless, in several cases, antibiotics characterized by all these features were ineffective for the treatment of respiratory tract infections. A typical paradigm represented the case o...
Source: Pulmonary Pharmacology and Therapeutics - January 8, 2020 Category: Respiratory Medicine Source Type: research

Low penetrance of antibiotics in the epithelial lining fluid. Experience from the use of inhaled antibiotics in patients with non CF-bronchiectasis
Publication date: Available online 28 December 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Theodoros Karampitsakos, Ourania Papaioannou, Maria Kaponi, Andreana Kozanidou, Georgios Hillas, Elisavet Stavropoulou, Demosthenes Bouros, Katerina DimakouAbstractPlasma drug concentrations, spectrum of antibacterial activity and minimum inhibitory concentration (MIC) had been widely considered as markers of the efficacy of antibiotics. Nonetheless, in several cases, antibiotics characterized by all these features were ineffective for the treatment of respiratory tract infections. A typical paradigm represented t...
Source: Pulmonary Pharmacology and Therapeutics - December 30, 2019 Category: Respiratory Medicine Source Type: research

The small quinolone derived compound HT61 enhances the effect of tobramycin against Pseudomonas aeruginosa in vitro and in vivo
In this study, we investigated the individual antimicrobial activity of HT61 alongside its capability to increase the efficacy of tobramycin against both a tobramycin sensitive laboratory reference strain (PAO1) and tobramycin resistant clinical isolates (RP73, NN2) of the gram-negative bacteria Pseudomonas aeruginosa (P. aeruginosa). Using broth microdilution methods, the MICs of HT61 against all strains were assessed, as well as the effect of HT61 in combination with tobramycin using both the chequerboard method and bacterial time-kill assays. A murine model of pulmonary infection was also used to evaluate the combinatio...
Source: Pulmonary Pharmacology and Therapeutics - December 28, 2019 Category: Respiratory Medicine Source Type: research

A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study
Publication date: Available online 26 December 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Luigino Calzetta, Maria Gabriella Matera, Marc F. Goldstein, William R. Fairweather, William W. Howard, Mario Cazzola, Paola RoglianiAbstractDoxofylline, an oral methylxanthine with bronchodilator and anti-inflammatory activities, offers a promising alternative to theophylline due to its superior efficacy/safety profile. No long-term studies on the efficacy and safety on doxofylline are currently available in asthma. The aim of the Long-term clinical trial on the Efficacy and Safety profile of Doxofylline in Asthm...
Source: Pulmonary Pharmacology and Therapeutics - December 27, 2019 Category: Respiratory Medicine Source Type: research

Prospective evaluation for inhalation devices in greek patients with COPD and asthma: The PAIR study
Publication date: Available online 24 December 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Theodoros Karampitsakos, Georgios Hillas, Eleftherios Zervas, Petros Bakakos, Grigorios Stratakos, Katerina Dimakou, Effrosyni Manali, Demosthenes Bouros, Spyridon Papiris, Argyrios Tzouvelekis, Adamidis Vasilios, Adamou Helen, Agelidis Xenophon, Albantakis Konstantinos, Anaplioti Aikaterini, Babalis Christos, Balasoulis George, Christou Konstantinos, Filippidou Elisavet Christina, Fothiantakis EmmanuelAbstractIntroductionChronic obstructive pulmonary disease (COPD) and asthma remain a major health burden. Adheren...
Source: Pulmonary Pharmacology and Therapeutics - December 25, 2019 Category: Respiratory Medicine Source Type: research

Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Greece
ConclusionsIPF is a risk factor for lung cancer development. In line with current literature, squamous cell carcinoma is the most common histologic subtype in patients with IPF. Large randomized controlled studies on the management of patients with IPF and lung cancer are sorely needed. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - December 24, 2019 Category: Respiratory Medicine Source Type: research

Efficacy of once-daily tiotropium Respimat in adults with asthma at GINA Steps 2–5
In conclusion, Tiotropium Respimat add-on therapy improves lung function, and may improve asthma control, in adults across disease severities.Graphical abstract (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - December 24, 2019 Category: Respiratory Medicine Source Type: research

Treatment response according to small airways disease status: The effects of high-strength extrafine pMDI beclomethasone dipropionate/formoterol fumarate in fixed dose combination in moderate uncontrolled asthmatic patients
Publication date: Available online 20 December 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Giovanna E. Carpagnano, Giulia Scioscia, Donato Lacedonia, Silvia Romana Stornelli, Carla Maria Irene Quarato, Piera Soccio, Onofrio Resta, Maria Pia Foschino BarbaroAbstractBackgroundInflammation in small airways is particularly clinically active in severe asthma but they still continue to be ignored as considered silent. Recently, the Atlantis study reports small airways involvement in 91% of the asthma population. Therefore in the era of phenotype driven therapy, the aim of this study was to verify if high-stre...
Source: Pulmonary Pharmacology and Therapeutics - December 20, 2019 Category: Respiratory Medicine Source Type: research

Impact of Azathioprine use in chronic hypersensitivity pneumonitis patients
Publication date: Available online 17 December 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): André Terras Alexandre, Natália Martins, Sara Raimundo, Natália Melo, Patrícia Caetano Mota, Hélder Novais e Bastos, José Miguel Pereira, Rui Cunha, Susana Guimarães, Conceição Souto Moura, António MoraisAbstractIntroductionSystemic corticosteroids are widely used in chronic hypersensitivity pneumonitis (CHP); however, there is not much evidence to support their use, besides being associated with significant side effects. Azathioprine (AZA) use ...
Source: Pulmonary Pharmacology and Therapeutics - December 18, 2019 Category: Respiratory Medicine Source Type: research

Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study
Publication date: Available online 16 December 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Francesco Menzella, Carla Galeone, Patrizia Ruggiero, Diego Bagnasco, Chiara Catellani, Nicola FacciolongoAbstractThe increasing knowledge on immuno-inflammatory pathways allowed the development of new therapeutic options in the field of severe refractory asthma (SRA). It is therefore very important to accurately identify phenotypes and endotypes of patients potentially eligible for innovative treatments. The aim of this study was to describe a cohort of patients affected by SRA referring to the Pneumology Unit of...
Source: Pulmonary Pharmacology and Therapeutics - December 17, 2019 Category: Respiratory Medicine Source Type: research

FEV1 recovery following methacholine challenge in asthma: Variability and comparison of methods
ConclusionMaximum reduction in FEV1 had the lowest variability. There was little difference between repetitions of the same methodology, as indicated by overlapping confidence intervals. There was a trend towards faster recovery following bolus challenge than with the incremental challenge. The results of this trial could be of value when designing future clinical trials using the methacholine challenge methodology. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - December 15, 2019 Category: Respiratory Medicine Source Type: research

The role of increased red cell distribution width as a negative prognostic marker in patients with COPD
Publication date: Available online 13 December 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Theodoros Karampitsakos, Katerina Dimakou, Ourania Papaioannou, Serafeim Chrysikos, Maria Kaponi, Demosthenes Bouros, Argyrios Tzouvelekis, Georgios HillasAbstractIntroductionChronic obstructive pulmonary disease (COPD) remains a major burden with no clinically applicable biomarkers.AimTo investigate the association of Red cell Distribution Width (RDW) values on admission with previous hospitalizations, need of non-invasive mechanical ventilation(NIMV) and long term oxygen therapy (LTOT)in patients with COPD.Metho...
Source: Pulmonary Pharmacology and Therapeutics - December 15, 2019 Category: Respiratory Medicine Source Type: research

The leukotriene receptor antagonist Montelukast can induce adverse skin reactions in asthmatic patients
Publication date: Available online 11 December 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Eleonora Di Salvo, Vincenzo Patella, Marco Casciaro, Sebastiano GangemiAbstractMontelukast the leukotriene receptor antagonist is an anti-inflammatory drug that causes bronchodilation and for this reason it is used to improve inflammatory states in asthma and allergic rhinitis. Montelukast is generally considered a safe drug with the occurrence of a few adverse drug reactions (ADRs) and anti-leucotrienes are usually well-tolerated by adults and young patients. Starting from these premises the purpose of this revie...
Source: Pulmonary Pharmacology and Therapeutics - December 11, 2019 Category: Respiratory Medicine Source Type: research

Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD
ConclusionsSteady-state PK parameters of budesonide, glycopyrronium, and formoterol were similar after 7 days’ dosing in the phase I PK study and after 24 weeks in the KRONOS PK sub-study. Systemic exposure to budesonide, glycopyrronium, and formoterol was generally comparable across treatments in the KRONOS PK sub-study, suggesting no meaningful drug–drug or within-formulation PK interactions. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - December 10, 2019 Category: Respiratory Medicine Source Type: research

Zileuton use and phenotypic features in asthma
ConclusionIn this retrospective study, zileuton response varies across asthmatics, with poorer response rates being associated with those with severe asthma and possibly obesity. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - December 10, 2019 Category: Respiratory Medicine Source Type: research

Real-world evaluation of the clinical safety and efficacy of fluticasone/formoterol FDC via the Revolizer® in patients with persistent asthma in India
Publication date: Available online 30 November 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Aloke Ghoshal, Pradyut Waghray, George Dsouza, Mahip Saluja, Mayank Agarwal, Ashish Goyal, Sneha Limaye, Akash Balki, Sudhir Bhatnagar, Manish Jain, Sharad Tikkiwal, Abhijit Vaidya, Meena Lopez, Rashmi Hegde, Jaideep GogtayAbstractThe combination of inhaled corticosteroids (ICS) and long-acting beta2-agonists (LABAs) is widely used for the management of asthma. This prospective, open-label, non-comparative, observational, 24-week multicentre study is the first real-world study from India to compare the efficacy an...
Source: Pulmonary Pharmacology and Therapeutics - December 1, 2019 Category: Respiratory Medicine Source Type: research

C-reactive protein as a biomarker of response to inhaled corticosteroids among patients with COPD
ConclusionWe did not find a reduced risk of moderate and/or severe COPD exacerbations among COPD patients with varying CRP levels currently exposed to ICS. However, low-grade systemic inflammation was associated with all-cause mortality among COPD patients. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 29, 2019 Category: Respiratory Medicine Source Type: research

Bronchoscopic delivery of aminocaproic acid as a treatment for pulmonary bleeding: A case series
ConclusionsEndobronchial administration of ε-aminocaproic acid during bronchoscopy may be a safe and efficacious option in the treatment and prevention of pulmonary bleeding. Further studies are necessary to better define ε-aminocaproic acid's safety profile, optimal routes of administration, and comparative effectiveness to tranexamic acid. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 26, 2019 Category: Respiratory Medicine Source Type: research

Editorial Board
Publication date: December 2019Source: Pulmonary Pharmacology & Therapeutics, Volume 59Author(s): (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 16, 2019 Category: Respiratory Medicine Source Type: research

Antistatic treatment and salbutamol dosing have variable effect on drug delivery of valved holding chambers
ConclusionVHCs marketed as antistatic are significantly affected by antistatic treatment. To ensure optimal drug delivery, salbutamol should be actuated to VHCs one puff at a time. Each VHC brand has its unique characteristic that affects drug delivery in a way that cannot be generalised to another VHC. There is a need for universal standardisation of VHCs.Key notesValved holding chambers (VHCs) that are marketed as antistatic are significantly affected by antistatic treatment. Multiple actuations before inhalation tend to decrease the drug delivery efficacy of VHCs. Each VHC brand has its unique characteristic that affect...
Source: Pulmonary Pharmacology and Therapeutics - November 1, 2019 Category: Respiratory Medicine Source Type: research

Interfering with airway nerves in cough associated with asthma
Publication date: Available online 1 November 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Akio Niimi, Kensuke Fukumitsu, Norihisa Takeda, Yoshihiro KanemitsuAbstractCough is a troublesome and often refractory symptom of asthma, which is associated with poor control of disease. The pathogenesis of asthmatic cough has mainly been attributed to bronchoconstriction, but recent evidence indicate that cough reflex hypersensitivity or neuronal dysfunction is a feature of asthma, even in those with mild stable disease. This is likely resistant to the mainstay treatment ICS/LABA which inhibits classic asthmatic ...
Source: Pulmonary Pharmacology and Therapeutics - November 1, 2019 Category: Respiratory Medicine Source Type: research

Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis
ConclusionsThe results of this meta-analysis show that LABA/LAMA combinations are consistently more effective than ICS/LABA FDCs for most of the evaluated outcomes. However, differences have also been observed between FDCs belonging to the same class. Across the investigated LABA/LAMA FDCs, glycopyrronium/indacaterol revealed a consistent and robust efficacy profile. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 20, 2019 Category: Respiratory Medicine Source Type: research

Evaluation of active neutrophil elastase in sputum of bronchiectasis and cystic fibrosis patients: A comparison among different techniques
Publication date: Available online 15 October 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Martina Oriano, Leonardo Terranova, Giovanni Sotgiu, Laura Saderi, Angela Bellofiore, Mariangela Retucci, Cinzia Marotta, Andrea Gramegna, Daniela Miglietta, Chiara Carnini, Paola Marchisio, James D. Chalmers, Stefano Aliberti, Francesco BlasiAbstractNeutrophil elastase (NE) is a crucial marker of neutrophilic inflammation. We aimed to compare different techniques to detect active NE in sputum samples of 50 Bronchiectasis (BE) and 50 Cystic Fibrosis (CF) patients. Three methods including a ProteaseTag® Active N...
Source: Pulmonary Pharmacology and Therapeutics - October 16, 2019 Category: Respiratory Medicine Source Type: research

Emerging targets for cough therapies; NK1 receptor antagonists
Publication date: Available online 14 October 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Huda Badri, Jaclyn A. SmithAbstractCough is mediated by vagal afferent fibres innervating the larynx and proximal airways. Pre-clinical studies suggest that vagal C fibres produce Substance P, one of the tachykinin family of neuropeptides, which has been shown to enhance cough via the neurokinin-1 (NK-1) receptor and studies in animal models have also shown that NK-1 antagonists are effective at blocking induced cough. In the past, tachykinin receptor antagonists have yielded disappointing results in treating asthm...
Source: Pulmonary Pharmacology and Therapeutics - October 15, 2019 Category: Respiratory Medicine Source Type: research

Safety, pharmacokinetics and pharmacodynamics of a novel anti-asthmatic drug, XC8, in healthy probands
ConclusionXC8 was safe and well tolerated. A phase 2 study is being performed to further evaluate the potential role of XC8 in asthma treatment.Trial registrationClinicalTrials.gov, NCT02882217. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 7, 2019 Category: Respiratory Medicine Source Type: research

Progress in cough hypersensitivity at the Tenth London International Cough Symposium 2018 (10th LICS 2018)
Publication date: Available online 26 September 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Kian Fan Chung, Lorcan McGarvey, Stuart B. Mazzone (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - September 27, 2019 Category: Respiratory Medicine Source Type: research

Comparison of anti-inflammatory mechanisms between doxofylline and theophylline in human monocytes
ConclusionsIn conclusion, our data support the growing hypothesis that doxofylline does not have a superimposable mechanism of action compared to theophylline, and this may both explain some differences in the risk/benefit ratio and may direct studies to tailor therapy for patients. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - September 27, 2019 Category: Respiratory Medicine Source Type: research

Isolated airways in equine respiratory pharmacology: They never lie
Publication date: Available online 22 September 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Luigino Calzetta, Elena Pistocchini, Beatrice Ludovica Ritondo, Paola Roncada, Giuseppe Cito, Domenico Britti, Maria Gabriella MateraAbstractPre-clinical studies on human isolated bronchi have relevant translational value in human in vivo, conversely no investigation has been performed to assess whether data resulting from equine isolated airways can have any translational application in asthmatic horses. Thus, a meta-regression analysis via random-effect method was carried out to correlate the pharmacological ch...
Source: Pulmonary Pharmacology and Therapeutics - September 24, 2019 Category: Respiratory Medicine Source Type: research

Editorial Board
Publication date: October 2019Source: Pulmonary Pharmacology & Therapeutics, Volume 58Author(s): (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - September 22, 2019 Category: Respiratory Medicine Source Type: research